The DOI matches its Crossref record; 21 of the 21 references it cites were found in a registry or an index.
Update of the guidelines for lupus anticoagulant detection
Open accessAbstract
One of the conclusions of the subcommittee meeting on Lupus Anticoagulant/Phospholipid dependent antibodies, held in Geneva on 2007, was the need to update the guidelines on Lupus Anticoagulant (LA) detection. Particular emphasis was given to several aspects discussed in this official communication. A new paragraph is dedicated to the patient selection, and aims to minimize inappropriate requests for LA testing. Modalities for blood collection and processing are fully delineated and the choice of tests is limited to dRVVT and a sensitive aPTT. Calculation of cut-off values for each diagnostic step are clearly stated. A final paragraph reports the interpretation of the results in general and in particular situations.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Similarly, persistently positive LAC and/or moderate/high Sapporo criteria aPL Abs (aCL IgG or IGM, or anti-b2GPI IgG or IgM) (10) were associated with HCQ use, OR 0.24 (0.06, 0.94), p=0.04”
From Hydroxychloroquine Use Is Associated with Lower Odds of Persistently Positive Antiphospholipid Antibodies and/or Lupus Anticoagulant in Systemic Lupus Erythematosus (2013) · cites this paper as [10]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“The last update of the guidelines for LA detection by the International Society on Thrombosis and Haemostasis Scientific and Standardization Subcommittee (ISTH-SSC) in 2009 12 has proven useful in achieving greater uniformity in performance and interpretation of LA testing.”
From Guidance from the Scientific and Standardization Committee for lupus anticoagulant/antiphospholipid antibodies of the International Society on Thrombosis and Haemostasis (2020) · cites this paper as [12]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“However, on other points, including testing in patients on anticoagulation, cutoff values, and calculation and interpretation of results, there was uncertainty or lack of agreement.12,15”
From Guidance from the Scientific and Standardization Committee for lupus anticoagulant/antiphospholipid antibodies of the International Society on Thrombosis and Haemostasis (2020) · cites this paper as [12]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“For samples from patients with no other causes of clotting time prolongation and LA assay confirmatory test results within reference intervals, the increasingly popular paradigm of integrated testing is sufficient to detect the presence of LA without performing the mixing test at all.6, 7, 8, 9, 26, 27, 28, 31, 33, 34”
From Lupus anticoagulant mixing tests for multiple reagents are more sensitive if interpreted with a mixing test‐specific cut‐off than index of circulating anticoagulant (2018) · cites this paper as [6]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“The mixing test is mainly to discriminate between the presence of an inhibitor and coagulation factor deficiencies such as those occurring in patients on conventional oral anticoagulants/vitamin K antagonists (VKA).”
From Mixing studies in lupus anticoagulant testing are required at least in some type of samples (2015) · cites this paper as [1]
Experimental — accuracy not yet measured
The cited source says what the claim attributes to it.
In the citing paper
“Guidelines recommend mixing tests are interpreted with either a mixing test specific cut‐off (MTC) or the index of circulating anticoagulant (ICA).”
The cited source says what the claim attributes to it.
In the citing paper
“There is no single test to detect all LA1, 6, 7, 8 and guidelines recommend performance of two different tests that represent different assay principles, the diluted Russell's viper venom time (dRVVT) and a LA‐sensitive activated partial thromboplastin time (APTT).6, 7, 8”
The cited source says what the claim attributes to it.
In the citing paper
“LA positivity was determined following the Scientific and Standardization Committee (SSC)/International Society on Thrombosis and Hemostasis (ISTH) recommendations at the time of testing.11,13”
From Lupus anticoagulant test persistence over time and its associations with future thrombotic events (2022) · cites this paper as [13]
The cited source says what the claim attributes to it.
In the citing paper
“The lupus anticoagulant assay (LA) followed international guidelines for the performance of this functional assay (54).”
From Autoantibodies in Systemic Lupus Erythematosus Target Mitochondrial RNA (2019) · cites this paper as [54]
The cited source says what the claim attributes to it.
In the citing paper
“According to ISTH/SSC (1) and CLSI (2) guidelines LAC identification should include three steps: screening for prolongation in a phospholipid-sensitive test, mixing with normal plasma to identify failure to correct and confirmation through result shortening in a phospholipid-rich test, (though in slightly different priority with CLSI).”
From Mixing studies in lupus anticoagulant testing are required at least in some type of samples (2015) · cites this paper as [1]
The cited source says what the claim attributes to it.
In the citing paper
“Results were expressed as normalized ratios and interpreted according to in-house calculated cut-off values calculated with the 99th percentile (1).”
From Mixing studies in lupus anticoagulant testing are required at least in some type of samples (2015) · cites this paper as [1]
The cited source says what the claim attributes to it.
In the citing paper
“Testing patients during VKA or other anticoagulant therapy for LAC remains a contentious issue and has been discouraged by official guidelines (1, 2) because of interpretational problems affecting the mixing test (8-10).”
From Mixing studies in lupus anticoagulant testing are required at least in some type of samples (2015) · cites this paper as [1]
The cited source says what the claim attributes to it.
In the citing paper
“Because there is no single assay sensitive to all LA antibodies, at least 2 coagulation tests based on different assay principles are recommended for LA detection [[11], [12], [13]].”
From Comparison of different algorithms for lupus anticoagulant detection: a single-center experience (2024) · cites this paper as [11]
The cited source says what the claim attributes to it.
In the citing paper
“Various interpretation indices, including percentage of correction (%Correct), screen-to-confirm ratio (SCR), and normalized SCR (NSCR), are suggested to determine the presence of LA in these phospholipid-dependent assays [[11], [12], [13]].”
From Comparison of different algorithms for lupus anticoagulant detection: a single-center experience (2024) · cites this paper as [11]
The cited source says what the claim attributes to it.
In the citing paper
“Laboratory tests for LA detection comprise complex and multistep coagulation testing procedures, including screening, confirmatory, and mixing tests [[11], [12], [13]], and heterogeneity in these is an important cause of interlaboratory variation.”
From Comparison of different algorithms for lupus anticoagulant detection: a single-center experience (2024) · cites this paper as [11]
The cited source says what the claim attributes to it.
In the citing paper
“The diluted Russell’s viper venom time (dRVVT) assay is the first recommended test for detecting LA due to its high sensitivity and specificity [14], while the LA-sensitive activated partial thromboplastin time (aPTT) assay can be used as a secondary test [[11], [12], [13], [14]].”
From Comparison of different algorithms for lupus anticoagulant detection: a single-center experience (2024) · cites this paper as [11]
The cited source says what the claim attributes to it.
In the citing paper
“LAC was determined using the STA-R Evolution Coagulation Analyzer (Diagnostica Stago, Asnières-sur-Seine, France) according to ISTH guidelines 1 applying dilute Russell ' s viper venomtime (dRVVT Screen and dRVVT Confirm, Diagnostica Stago, Asnières-sur-Seine, France) and a sensitive activated partial thromboplastin time (aPTT) with silica as an activator (PTT-LA, Diagnostica Stago, Asnières-sur-”
From Clinical Relevance of Isolated Lupus Anticoagulant Positivity in Patients with Thrombotic Antiphospholipid Syndrome (2021) · cites this paper as [1]
The cited source says what the claim attributes to it.
In the citing paper
“This study supports the dRVVT as the preferred assay to detect LAC. 1”
From Clinical Relevance of Isolated Lupus Anticoagulant Positivity in Patients with Thrombotic Antiphospholipid Syndrome (2021) · cites this paper as [1]
The cited source says what the claim attributes to it.
In the citing paper
“and LAC was performed according to the ISTH guidelines. 1,34”
From Clinical Relevance of Isolated Lupus Anticoagulant Positivity in Patients with Thrombotic Antiphospholipid Syndrome (2021) · cites this paper as [1]
The cited source says what the claim attributes to it.
In the citing paper
“LA was determined using two clotting assays as recommended by the 2009 International Society on Thrombosis and Haemostasis (ISTH) guidelines, 21 which were applicable at the time of the study: APTT by Diagnostica Stago and dRVVT by HYPHEN BioMed. 21”
From Single or triple positivity for antiphospholipid antibodies in “carriers” or symptomatic patients: Untangling the knot (2021) · cites this paper as [21]
The cited source says what the claim attributes to it.
In the citing paper
“However, the samples were analyzed before the publication of these new guidelines and therefore interpreted according to the guidelines that were applicable at this time. 21”
From Single or triple positivity for antiphospholipid antibodies in “carriers” or symptomatic patients: Untangling the knot (2021) · cites this paper as [21]
The check wasn’t confident either way, so it gives no verdict — never disputed.
In the citing paper
“The majority of survey participants indicated that the number should be at least 40, which seems reasonable to guarantee an overall normal clotting factor activity. 12”
From Guidance from the Scientific and Standardization Committee for lupus anticoagulant/antiphospholipid antibodies of the International Society on Thrombosis and Haemostasis (2020) · cites this paper as [12]
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
MIYAKIS, S., LOCKSHIN, M. D., ATSUMI, T., BRANCH, D. W., BREY, R. L., CERVERA, R., DERKSEN, R. H. W. M., DE GROOT, P. G., KOIKE, T., MERONI, P. L., et al. (2006) · Journal of Thrombosis and Haemostasis · doi:10.1111/j.1538-7836.2006.01753.x · Cited by 7,203
Self-citationBrandt, J. T., Triplett, D. A., Alving, B. M., & Scharrer, I. (1995) · PubMed · Cited by 1,164
Brandt, J. T., Triplett, D. A., Alving, B., & Scharrer, I. (1995) · Thrombosis and Haemostasis · doi:10.1055/s-0038-1649901 · Cited by 993
Rand, J. H., Wu, X.-X., Quinn, A. S., Chen, P. P., Hathcock, J. J., & Taatjes, D. J. (2008) · Blood · doi:10.1182/blood-2008-03-144204 · Cited by 215
Self-citationDetection and Quantitative Evaluation of Lupus Circulating Anticoagulant Activity
Rosner, E., Pauzner, R., Lusky, A., Modan, M., & Many, A. (1987) · Thrombosis and Haemostasis · doi:10.1055/s-0038-1651083 · Cited by 188
Galli, M., Finazzi, G., Bevers, E. M., & Barbui, T. (1995) · Blood · doi:10.1182/blood.v86.2.617.bloodjournal862617 · Cited by 146
Self-citationA Hexagonal (II) Phase Phospholipid Neutralization Assay for Lupus Anticoagulant Identification
Triplett, D. A., Barna, L. K., & Unger, G. A. (1993) · Thrombosis and Haemostasis · doi:10.1055/s-0038-1649671 · Cited by 132
The Textarin/Ecarin Ratio: A Confirmatory Test for Lupus Anticoagulants
Triplett, D. A., Stocker, K. F., Unger, G. A., & Barna, L. K. (1993) · Thrombosis and Haemostasis · doi:10.1055/s-0038-1649701 · Cited by 110
Jennings, I., Kitchen, S., Woods, T. A. L., Preston, F. E., & Greaves, M. (1997) · Thrombosis and Haemostasis · doi:10.1055/s-0038-1656080 · Cited by 103
Meijer, P., Vermylen, J., & Arnout, J. (1999) · Thrombosis and Haemostasis · doi:10.1055/s-0037-1614601 · Cited by 96
Cited by
Sorted by citations
Items 301–400 of 1,001
Current Promising Biomarkers and Methods in the Diagnostics of Antiphospholipid Syndrome: A Review
Bradáčová, P., Slavík, L., Úlehlová, J., Skoumalová, A., Ullrychová, J., Procházková, J., Hluší, A., Manukyan, G. P., & Kriegová, E. (2021) · Biomedicines · doi:10.3390/biomedicines9020166 · Cited by 33
Venous thromboembolism: Predicting recurrence and the need for extended anticoagulation
Barnes, G. D., Kanthi, Y. M., & Froehlich, J. B. (2015) · Vascular Medicine · doi:10.1177/1358863x14566429 · Cited by 34
Sciascia, S., Roccatello, D., Bertero, M. T., Simone, D. D., Cosseddu, D., Vaccarino, A., Bazzan, M., Rossi, D., Garcia-Fernandez, C., Ceberio, L., et al. (2012) · Inflammation Research · doi:10.1007/s00011-012-0468-0 · Cited by 33
Devreese, K. M. J., & Van Hoecke, F. (2011) · Thrombosis Research · doi:10.1016/j.thromres.2011.06.023 · Cited by 32
Variability and diagnostic utility of antiphospholipid antibodies including lupus anticoagulants
Favaloro, E. J. (2013) · International Journal of Laboratory Hematology · doi:10.1111/ijlh.12072 · Cited by 32
Aldar, H., Lapa, A., Bellini, B. S., Sinicato, N. A., Postal, M., Fernandes, P. T., Costallat, L., Marini, R., & Appenzeller, S. (2012) · Lupus · doi:10.1177/0961203312451201 · Cited by 32
Marchetti, T., de Moerloose, P., & Gris, J. (2016) · Journal of Thrombosis and Haemostasis · doi:10.1111/jth.13257 · Cited by 33
Perioperative Management of Antiphospholipid Antibody-Positive Patients
Saunders, K. H., Erkan, D., & Lockshin, M. D. (2014) · Current Rheumatology Reports · doi:10.1007/s11926-014-0426-7 · Cited by 32
Recent developments in our understanding of the antiphospholipid syndrome
de Groot, P. G., Meijers, J. C. M., & Urbanus, R. T. (2012) · International Journal of Laboratory Hematology · doi:10.1111/j.1751-553x.2012.01414.x · Cited by 31
Optimisation of lupus anticoagulant tests: should test samples always be mixed with normal plasma?
Pennings, M., de Groot, P., Meijers, J., Huisman, A., Derksen, R., & Urbanus, R. (2014) · Thrombosis and Haemostasis · doi:10.1160/th14-02-0122 · Cited by 31
Favaloro, E. J. (2018) · Clinical Chemistry and Laboratory Medicine (CCLM) · doi:10.1515/cclm-2018-1041 · Cited by 31
Long-term follow-up of antiphospholipid syndrome: real-life experience from a single center
Serrano, R., Pons‐Estel, G., Espinosa, G., Quintana, R., Reverter, J. C., Tàssies, D., Monteagudo, J., & Cervera, R. (2020) · Lupus · doi:10.1177/0961203320933009 · Cited by 31
Pardos‐Gea, J., Marques-Soares, J. R., Buján, S., Ordi, J., & Alijotas‐Reig, J. (2021) · Rheumatology · doi:10.1093/rheumatology/keab475 · Cited by 31
The Effects of Indirect- and Direct-Acting Anticoagulants on Lupus Anticoagulant Assays
Seheult, J. N., Meyer, M. P., Bontempo, F. A., & Chibisov, I. (2017) · American Journal of Clinical Pathology · doi:10.1093/ajcp/aqx035 · Cited by 31
Ellwood, L., Rubie, J., Barancewicz, A., & Exner, T. (2013) · Thrombosis and Haemostasis · doi:10.1160/th12-11-0842 · Cited by 30
Laboratory methods to detect antiphospholipid antibodies
Krilis, S. A., & Giannakopoulos, B. (2014) · Hematology · doi:10.1182/asheducation-2014.1.321 · Cited by 30
Cheng, C., Zhang, Y., Denas, G., Du, Y., Jing, Z., & Pengo, V. (2019) · Internal and Emergency Medicine · doi:10.1007/s11739-018-02021-z · Cited by 30
Self-citationBaker, S. A., Jin, J., Pfaffroth, C., Vu, T., & Zehnder, J. L. (2021) · Research and Practice in Thrombosis and Haemostasis · doi:10.1002/rth2.12472 · Cited by 30
Prophylaxis and treatment of COVID-19 related venous thromboembolism
Kaptein, F. H. J., Stals, M. A. M., Huisman, M. V., & Klok, F. A. (2021) · Postgraduate Medicine · doi:10.1080/00325481.2021.1891788 · Cited by 31
Egri, N., Bentow, C., Rubio, L., Norman, G. L., López-Sañudo, S., Mähler, M., Pérez-Isidro, A., Cervera, R., Viñas, O., Espinosa, G., et al. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.754469 · Cited by 30
Testing for Lupus Anticoagulants
Moore, G. W. (2022) · Seminars in Thrombosis and Hemostasis · doi:10.1055/s-0042-1744363 · Cited by 30
Strategies for Managing Heparin Therapy in Patients with Antiphospholipid Antibody Syndrome
Mehta, T. P., Smythe, M. A., & Mattson, J. C. (2011) · Pharmacotherapy The Journal of Human Pharmacology and Drug Therapy · doi:10.1592/phco.31.12.1221 · Cited by 30
Sciascia, S., Sanna, G., Murru, V., Khamashta, M. A., & Bertolaccini, M. L. (2013) · Thrombosis Research · doi:10.1016/j.thromres.2013.12.001 · Cited by 30
Cardiovascular risk profiles in a lupus cohort: what do different calculators tell us?
Boulos, D., Koelmeyer, R., Morand, E. F., & Hoi, A. Y.-B. (2017) · Lupus Science & Medicine · doi:10.1136/lupus-2017-000212 · Cited by 30
Chayouâ, W., Yin, D., Kelchtermans, H., Moore, G. W., Gris, J., Musiał, J., Zuily, S., Cate, H. T., de Laat, B., & Devreese, K. M. J. (2020) · Thrombosis and Haemostasis · doi:10.1055/s-0040-1714653 · Cited by 30
Gao, R., Zeng, R., Qing, P., Cheng, M., Cheng, K., Zhang, S., Chen, H., Jin, X., Qin, L., & Li, T. (2021) · American Journal of Reproductive Immunology · doi:10.1111/aji.13470 · Cited by 29
False-positive lupus anticoagulant in patients receiving rivaroxaban
Góralczyk, T., Iwaniec, T., Wypasek, E., & Undas, A. (2014) · Blood Coagulation & Fibrinolysis · doi:10.1097/mbc.0000000000000235 · Cited by 29
Hoxha, A., Calligaro, A., Tonello, M., Ramonda, R., Carletto, A., Paolazzi, G., Bortolotti, R., Ross, T. D., Grava, C., Boaretto, M., et al. (2015) · Joint Bone Spine · doi:10.1016/j.jbspin.2015.04.020 · Cited by 29
Laboratory testing for antiphospholipid syndrome
Pengo, V., Banzato, A., Bison, E., Denas, G., Zoppellaro, G., Bracco, A., Jose, S. P., Hoxha, A., & Ruffatti, A. (2016) · International Journal of Laboratory Hematology · doi:10.1111/ijlh.12507 · Cited by 29
Self-citationAntiphospholipid syndrome, “the best prophet of the future”
Amengual, O., & Atsumi, T. (2018) · Modern Rheumatology · doi:10.1080/14397595.2018.1435988 · Cited by 30
Heikal, N., Jaskowski, T. D., Malmberg, E. M., Lakos, G., Branch, D. W., & Tebo, A. E. (2014) · Clinical & Experimental Immunology · doi:10.1111/cei.12573 · Cited by 29
Antiphospholipid antibody profile: implications for the evaluation and management of patients
Tincani, A., Andréoli, L., Casu, C., Cattaneo, R., & Meroni, P. L. (2010) · Lupus · doi:10.1177/0961203310361491 · Cited by 29
Galli, M. (2009) · Journal of Thrombosis and Haemostasis · doi:10.1111/j.1538-7836.2009.03689.x · Cited by 29
Self-citationFabris, M., Giacomello, R., Poz, A., Pantarotto, L., Tanzi, N., Curcio, F., & Tonutti, E. (2014) · Autoimmunity Highlights · doi:10.1007/s13317-014-0061-3 · Cited by 29
Hoylaerts, M., & Devreese, K. M. J. (2010) · Thrombosis and Haemostasis · doi:10.1160/th10-06-0410 · Cited by 29
The association of antiphospholipid antibodies with intrauterine fetal death: A case–control study
Helgadóttir, L. B., Skjeldestad, F. E., Jacobsen, A. F., Sandset, P. M., & Jacobsen, E. (2011) · Thrombosis Research · doi:10.1016/j.thromres.2011.11.029 · Cited by 29
Zhang, S., Wu, Z., Chen, S., Li, J., Wen, X., Li, L., Zhang, W., Zhao, J., Zhang, F., & Li, Y. (2016) · Scientific Reports · doi:10.1038/srep23839 · Cited by 29
Interference of DOACs in different DRVVT assays for diagnosis of lupus anticoagulants
Flieder, T., Weiser, M., Eller, T., Dittrich, M. T., von Bargen, K., Alban, S., Kühn, J., Knabbe, C., & Birschmann, I. (2018) · Thrombosis Research · doi:10.1016/j.thromres.2018.03.009 · Cited by 29
High risk of adverse pregnancy outcomes in women with a persistent lupus anticoagulant
Gebhart, J., Posch, F., Koder, S., Quehenberger, P., Perkmann, T., Kuessel, L., Ay, C., & Pabinger, I. (2019) · Blood Advances · doi:10.1182/bloodadvances.2018026948 · Cited by 29
Beyond the “syndrome”: Antiphospholipid antibodies as risk factors
Andréoli, L., & Tincani, A. (2011) · Arthritis & Rheumatism · doi:10.1002/art.33341 · Cited by 29
Diagnosis and therapy of antiphospholipid syndrome
Pengo, V., Denas, G., Jose, S. P., Zoppellaro, G., Bison, E., Banzato, A., Hoxha, A., & Ruffatti, A. (2015) · Polskie Archiwum Medycyny Wewnętrznej · doi:10.20452/pamw.3051 · Cited by 28
Self-citationArterial Embolisms and Thrombosis in Upper Extremity Ischemia
Skeik, N., Soo-Hoo, S., Porten, B. R., Graber, J. N., Alden, P. B., Cragg, A. H., Alexander, J. Q., Rizvi, A. Z., Manunga, J. M., Garberich, R., et al. (2015) · Vascular and Endovascular Surgery · doi:10.1177/1538574415596740 · Cited by 28
Shi, H., Teng, J., Sun, Y., Wu, X., Hu, Q., Liu, H.-L., Cheng, X., Yin, Y., Ye, J., Chen, P. P., et al. (2017) · Clinical Rheumatology · doi:10.1007/s10067-017-3549-1 · Cited by 28
Direct oral anticoagulants: an alternative treatment for thrombotic antiphospholipid syndrome?
Rességuier, A.-S., Pereira, B., Rieu, V., Guenno, G. L., Grobost, V., & Ruivard, M. (2017) · Lupus · doi:10.1177/0961203317701841 · Cited by 28
Laurent, C., Ricard, L., Nguyen, Y., Boffa, J. J., Rondeau, É., Gerotziafas, G., Elalamy, I., Deriaz, S., MOREUIL, C. D., Planche, V., et al. (2023) · RMD Open · doi:10.1136/rmdopen-2022-002534 · Cited by 28
Gonzalo, E. S., Toldos, Ó., Martínez-Vidal, M. P., Ordoñez, M. C., Santiago, B., Fernández‐Nebro, A., Loza, E., García, I., León, M., Pablos, J. L., et al. (2012) · Arthritis Research & Therapy · doi:10.1186/ar3856 · Cited by 28
Mayer-Pickel, K. I., Stern, C., Eberhard, K., Lang, U., Obermayer-Pietsch, B. M., & Cervar-Zivkovic, M. (2018) · Journal of Reproductive Immunology · doi:10.1016/j.jri.2018.04.002 · Cited by 28
Ogata, Y., Fujieda, Y., Sugawara, M., Sato, T., Ohnishi, N., Kono, M., Kato, M., Oku, K., Amengual, O., & Atsumi, T. (2020) · Rheumatology · doi:10.1093/rheumatology/keaa542 · Cited by 28
Response to “Lupus anticoagulant is frequent in patients with Covid‐19” (JTH‐2020‐00483)
Tang, N. (2020) · Journal of Thrombosis and Haemostasis · doi:10.1111/jth.14890 · Cited by 28
Devignes, J., Smaïl‐Tabbone, M., Hervé, A., Cagninacci, G., Devignes, M., Lecompte, T., Zuily, S., & Wahl, D. (2019) · International Journal of Laboratory Hematology · doi:10.1111/ijlh.13094 · Cited by 27
Lupus anticoagulant detection: out of control?
Moore, G. W., Brown, K. L., Bromidge, E. S., Drew, A. J., & Ledford‐Kraemer, M. R. (2013) · International Journal of Laboratory Hematology · doi:10.1111/ijlh.12006 · Cited by 27
Del Ross, T., Ruffatti, A., Cuffaro, S., Tonello, M., Calligaro, A., Favaro, M., Facchinetti, M., Hoxha, A., & Punzi, L. (2015) · Thrombosis Research · doi:10.1016/j.thromres.2015.08.019 · Cited by 27
De novo neonatal antiphospholipid syndrome: A case report and review of the literature
Gordon, O. M., Almagor, Y., Fridler, D., Mandel, A., Qutteineh, H., Yanir, A. D., Reif, S. S., & Revel‐Vilk, S. (2014) · Seminars in Arthritis and Rheumatism · doi:10.1016/j.semarthrit.2014.04.003 · Cited by 27
Núñez‐Álvarez, C. A., Hernández‐Molina, G., Bermúdez-Bermejo, P., Zamora-Legoff, V., Hernández‐Ramírez, D. F., Olivares‐Martínez, E., & Cabral, A. R. (2018) · Thrombosis Research · doi:10.1016/j.thromres.2018.12.023 · Cited by 27
Liu, T., Gu, J., Wan, L., Hu, Q., Teng, J., Liu, H., Cheng, X., Ye, J., Su, Y., Sun, Y., et al. (2019) · Thrombosis Research · doi:10.1016/j.thromres.2019.11.029 · Cited by 27
Hell, L., Lurger, K., Mauracher, L., Grilz, E., Reumiller, C. M., Schmidt, G. J., Ercan, H., Koder, S., Assinger, A., Basílio, J., et al. (2020) · Experimental & Molecular Medicine · doi:10.1038/s12276-019-0358-4 · Cited by 27
Kumano, O., & Moore, G. W. (2018) · Research and Practice in Thrombosis and Haemostasis · doi:10.1002/rth2.12069 · Cited by 26
Pradella, P., Azzarini, G., Santarossa, L., Caberlotto, L., Bardin, C., Poz, A., D’Aurizio, F., & Giacomello, R. (2013) · Clinical Chemistry and Laboratory Medicine (CCLM) · doi:10.1515/cclm-2012-0382 · Cited by 26
The Role of Antiphospholipid Antibodies in COVID-19
Stelzer, M., Henes, J. C., & Saur, S. J. (2021) · Current Rheumatology Reports · doi:10.1007/s11926-021-01041-7 · Cited by 26
Benjamin, L. A., Paterson, R. W., Moll, R., Pericleous, C., Brown, R. L., Mehta, P. R., Athauda, D. S., Ziff, O. J., Heaney, J., Checkley, A. M., et al. (2021) · EClinicalMedicine · doi:10.1016/j.eclinm.2021.101070 · Cited by 26
Hoirisch-Clapauch, S., & Nardi, A. E. (2014) · Schizophrenia Research · doi:10.1016/j.schres.2014.08.011 · Cited by 26
Role of thrombophilic factors in full-term infants with neonatal encephalopathy
Harteman, J. C., Groenendaal, F., Benders, M. J. N. L., Huisman, A., Blom, H. J., & de Vries, L. S. (2012) · Pediatric Research · doi:10.1038/pr.2012.150 · Cited by 26
Mattia, E., Ruffatti, A., Tonello, M., Meneghel, L., Robecchi, B., Pittoni, M., Gallo, N., Salvan, E., Teghil, V., Punzi, L., et al. (2014) · Clinical Chemistry and Laboratory Medicine (CCLM) · doi:10.1515/cclm-2014-0039 · Cited by 26
Mok, C. C., Chan, P. T., Ho, L. Y., Yu, K. L., & To, C. H. (2013) · Medicine · doi:10.1097/md.0b013e31829cae47 · Cited by 26
Red cell distribution width and the risk of cerebral vein thrombosis: A case–control study
Maino, A., Abbattista, M., Bucciarelli, P., Artoni, A., Passamonti, S. M., Lanfranconi, S., & Martinelli, I. (2016) · European Journal of Internal Medicine · doi:10.1016/j.ejim.2016.10.017 · Cited by 26
Cáliz, R., Fontecha, P. D. D. C., Galindo-Izquierdo, M., Longo, F. J. L., Zamora, M. Á. M., Santamaría, A., Pliego, O. A., Lozano, M. J. C., Beltrán, M. P. D., Carmona, L., et al. (2019) · Reumatología Clínica · doi:10.1016/j.reuma.2018.11.003 · Cited by 26
Tokutake, T., Baba, H., Shimada, Y., Takeda, W., Sato, K., Hiroshima, Y., Kirihara, T., Shimizu, I., Nakazawa, H., Kobayashi, H., et al. (2016) · PLoS ONE · doi:10.1371/journal.pone.0157835 · Cited by 26
Posch, F., Gebhart, J., Rand, J. H., Koder, S., Quehenberger, P., Pengo, V., Ay, C., & Pabinger, I. (2017) · BMC Medicine · doi:10.1186/s12916-017-0807-7 · Cited by 25
“LA was diagnosed according to Scientific and Standardization Committee (SSC)/ International Society on Thrombosis and Hemostasis (ISTH) recommendations [17, 18].”
MethodSelf-citationTebo, A. E., Willis, R., Jaskowski, T. D., Guerra, M. M., Pierangeli, S. S., Salmon, J. E., Petri, M., & Branch, D. W. (2016) · Clinica Chimica Acta · doi:10.1016/j.cca.2016.06.025 · Cited by 25
Acquired and Inherited Thrombophilia Disorders in Pregnancy
Pierangeli, S. S., Leader, B., Barilaro, G., Willis, R., & Branch, D. W. (2011) · Obstetrics and Gynecology Clinics of North America · doi:10.1016/j.ogc.2011.02.016 · Cited by 25
Montaruli, B., Luna, E. D., Erroi, L., Marchese, C. A., Mengozzi, G., Napoli, P., Nicolò, C., Romito, A., Bertero, M., Sivera, P., et al. (2016) · International Journal of Laboratory Hematology · doi:10.1111/ijlh.12466 · Cited by 25
Moore, G. W., Culhane, A. P., Maloney, J. C., Archer, R. A., Breen, K. A., & Hunt, B. J. (2015) · Blood Coagulation & Fibrinolysis · doi:10.1097/mbc.0000000000000486 · Cited by 25
Prevention of thrombosis in antiphospholipid syndrome
Lim, W. (2016) · Hematology · doi:10.1182/asheducation-2016.1.707 · Cited by 25
Sciascia, S., Radin, M., Cecchi, I., Rubini, E., Bazzan, M., & Roccatello, D. (2018) · Seminars in Arthritis and Rheumatism · doi:10.1016/j.semarthrit.2018.04.001 · Cited by 25
The Russell viper venom time (RVVT) test for investigation of lupus anticoagulant (LA)
Favaloro, E. J. (2019) · American Journal of Hematology · doi:10.1002/ajh.25606 · Cited by 25
Tonello, M., Bison, E., Cattini, M. G., Pontara, E., Iaccarino, L., Denas, G., Cheng, C., & Pengo, V. (2021) · Clinical Chemistry and Laboratory Medicine (CCLM) · doi:10.1515/cclm-2021-0692 · Cited by 25
Self-citationMore on: laboratory investigation of lupus anticoagulants: mixing studies are sometimes required
Tripodi, A., & Pengo, V. (2011) · Journal of Thrombosis and Haemostasis · doi:10.1111/j.1538-7836.2011.04440.x · Cited by 25
Self-citationKumano, O., & Moore, G. W. (2019) · Research and Practice in Thrombosis and Haemostasis · doi:10.1002/rth2.12245 · Cited by 24
Malbora, B., & Bilaloğlu, E. (2015) · Pediatric Hematology and Oncology · doi:10.3109/08880018.2015.1065302 · Cited by 24
Bortoluzzi, A., Chighizola, C. B., Fredi, M., Raschi, E., Bodio, C., Privitera, D., Gonelli, A., Silvagni, E., Govoni, M., Cavazzana, I., et al. (2020) · Frontiers in Immunology · doi:10.3389/fimmu.2020.572876 · Cited by 24
Favaloro, E. J., Mohammed, S., Vong, R., McVicker, W., Chapman, K., Swanepoel, P., Kershaw, G., Cai, N., Just, S., Connelly, L., et al. (2021) · American Journal of Clinical Pathology · doi:10.1093/ajcp/aqab004 · Cited by 24
Serum cytokines to predict systemic lupus erythematosus clinical and serological activity
Moreno‐Torres, V., Castejón, R., Martínez‐Urbistondo, M., Gutiérrez‐Rojas, Á., Vázquez‐Comendador, J., Tutor, P., Campo, P. D., Mellor‐Pita, S., Rosado, S., & Vargas‐Núñez, J. (2022) · Clinical and Translational Science · doi:10.1111/cts.13283 · Cited by 25
Prolonged Activated Partial Thromboplastin Time
Ames, P. R. J., Graf, M. E., Archer, J., Scarpato, N., & Iannaccone, L. (2014) · Clinical and Applied Thrombosis/Hemostasis · doi:10.1177/1076029614541516 · Cited by 24
Tagariello, G., Radossi, P., Salviato, R., Zardo, M., Valentin, L. D., Basso, M., & Castaman, G. (2017) · PubMed Central · doi:10.2450/2016.0047-16 · Cited by 24
Serological evolution in women with positive antiphospholipid antibodies
Riancho‐Zarrabeitia, L., Daroca, G., Muñoz, P., López‐Hoyos, M., Haya, A., & Martínez-Taboada, V. M. (2017) · Seminars in Arthritis and Rheumatism · doi:10.1016/j.semarthrit.2017.05.001 · Cited by 24
Zuo, Y., Barbhaiya, M., & Erkan, D. (2018) · Current Rheumatology Reports · doi:10.1007/s11926-018-0775-8 · Cited by 25
Pericleous, C., D’Souza, A., McDonnell, T. C. R., Ripoll, V. M., Leach, O. A., Isenberg, D. A., Giles, I., & Rahman, A. (2019) · Rheumatology · doi:10.1093/rheumatology/kez239 · Cited by 24
Evaluation of novel assays for the detection of autoantibodies in antiphospholipid syndrome
Sciascia, S., Radin, M., Ramirez, C., Seaman, A., Bentow, C., Casas, S., Cecchi, I., Rubini, E., Foddai, S. G., Baldovino, S., et al. (2020) · Autoimmunity Reviews · doi:10.1016/j.autrev.2020.102641 · Cited by 24
Conti, F., Ceccarelli, F., Perricone, C., Massaro, L., Cipriano, E., Pacucci, V. A., Truglia, S., Miranda, F., Morello, F., Alessandri, C., et al. (2014) · Immunologic Research · doi:10.1007/s12026-014-8609-x · Cited by 23
Urbanski, G., Caillon, A., Poli, C., Kauffenstein, G., Bégorre, M.-A., Loufrani, L., Henrion, D., & Belizna, C. C. (2018) · PLoS ONE · doi:10.1371/journal.pone.0206814 · Cited by 23
Pontara, E., Cattini, M. G., Cheng, C., Bison, E., Denas, G., & Pengo, V. (2020) · Journal of Thrombosis and Haemostasis · doi:10.1111/jth.15199 · Cited by 23
Self-citationNaranjo, L., Stojanovich, L., Djoković, A., Andréoli, L., Tincani, A., Maślińska, M., Sciascia, S., Infantino, M. G., Garcinuño, S., Kostyra-Grabczak, K., et al. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.957201 · Cited by 23
Murarasu, A., Guettrot-Imbert, G., Guern, V. L., Yelnik, C., Queyrel, V., SCHLEINITZ, N., Ferreira-Maldent, N., Diot, É., Urbanski, G., Pannier, E., et al. (2022) · The Lancet Rheumatology · doi:10.1016/s2665-9913(22)00308-3 · Cited by 23
Frackiewicz, A., Kałaska, B., Mikłosz, J., & Mogielnicki, A. (2023) · Thrombosis Journal · doi:10.1186/s12959-023-00501-7 · Cited by 23
Płazak, W., Gryga, K., Milewski, M., Podolec, M., Kostkiewicz, M., Podolec, P. S., & Musiał, J. (2011) · Lupus · doi:10.1177/0961203311399607 · Cited by 23
Vitamin D and antiphospholipid syndrome: A retrospective cohort study and meta-analysis
Riancho‐Zarrabeitia, L., Cubería, M., Muñoz, P., López‐Hoyos, M., García-Canale, S., García‐Unzueta, M. T., Hernández, J. L., & Martínez-Taboada, V. M. (2017) · Seminars in Arthritis and Rheumatism · doi:10.1016/j.semarthrit.2017.10.007 · Cited by 23
Scambi, C., Ugolini, S., Tonello, M., Bortolami, O., Franceschi, L. D., Castagna, A., Lotti, V., Corbella, M., Raffaelli, R., Caramaschi, P., et al. (2019) · American Journal of Reproductive Immunology · doi:10.1111/aji.13185 · Cited by 23
What is the appropriate anticoagulation strategy for thrombotic antiphospholipid syndrome?
Arachchillage, D. J., & Laffan, M. (2020) · British Journal of Haematology · doi:10.1111/bjh.16431 · Cited by 26
Ichinose, A., Osaki, T., & Souri, M. (2021) · Thrombosis and Haemostasis · doi:10.1055/a-1496-8527 · Cited by 23
Pozzi, N., Banzato, A., Bettin, S., Bison, E., Pengo, V., & Filippis, V. D. (2010) · Protein Science · doi:10.1002/pro.387 · Cited by 23
Self-citation
Metadata
- Authors
- PENGO, V., TRIPODI, A., REBER, G., RAND, J. H., ORTEL, T. L., GALLI, M., & DE GROOT, P. G.
- Affiliations
- University of Padua (IT)
- University of Milan (IT)
- University Hospital of Geneva (CH)
- Montefiore Medical Center (US)
- Duke Medical Center (US)
- Corresponding author
- PENGO, V.
- Venue
- Journal of Thrombosis and Haemostasis
- Publisher
- Elsevier BV
- Published
- 2009-10
- Volume
- 7
- Issue
- 10
- Pages
- 1737-1740
- ISSN
- 1538-7836 (ISSN-L)
- OpenAlex
- W2069797332
- Cited by
- 1,197
- References
- 21
- Citations by year
- 2026: 20 · 2025: 32 · 2024: 53 · 2023: 55 · 2022: 65 · 2021: 89 · 2020: 99 · 2019: 101 · 2018: 88 · 2017: 82 · 2016: 80 · 2015: 75 · 2014: 81 · 2013: 69 · 2012: 82
- FWCI
- 48.25
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Licence
- Locations
- Journal of Thrombosis and Haemostasis (publishedVersion)
- PubMed (publishedVersion)
- Padua Research Archive (University of Padova) (submittedVersion)
- Topics
- Health Sciences › Medicine › Rheumatology › Systemic Lupus Erythematosus Research
- Health Sciences › Medicine › Hematology › Blood Coagulation and Thrombosis Mechanisms
- Health Sciences › Medicine › Hematology › Heparin-Induced Thrombocytopenia and Thrombosis
- Keywords
- lupus anticoagulant, patient selection, activated partial thromboplastin time, cut-off values, interpretation of results, diagnostic guidelines
- MeSH terms
- Anticoagulants, Blood Coagulation, Blood Specimen Collection, Female, Humans, Indicators and Reagents, Male, Partial Thromboplastin Time, Phospholipids, Pregnancy, Pregnancy Complications, Hematologic, Prothrombin Time, Specimen Handling, Vitamin K, Artifacts, Lupus Coagulation Inhibitor, Antiphospholipid Syndrome, Patient Selection
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
